GUMDROP : NCI 09-C-0195 A Phase 2 Trial of Bevacizumab, Lenalidomide, Docetaxel, and Prednisone (ART-P) for Treatment of Metastatic Castrate-Resistant Prostate Cancer

Created by Marte, Jenn (NIH/NCI) [E], last modified by Channing Paller on Apr 14, 2012

Description:

A previous study at the NCI combined docetaxel, prednisone, bevacizumab and thalidomide, with promising results. However, frequent dose reductions of thalidomide were required due to side effects. Lenalidomide is similar to thalidomide, has been shown to be well-tolerated, and may serve as an effective substitute. In this phase II trial, the combination of docetaxel, prednisone, bevacizumab, and lenalidomide will be evaluated for safety and efficacy.

Link:

http://www.clinicaltrials.gov/ct2/show/NCT00942578

Site:

NCI

Principal Investigator:

Bill Dahut